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Background: Multimorbidity has an adverse effect on health outcomes in hospitalized individuals with chronic heart
failure (CHF), but the modulating effect of multidisciplinary management is unknown. Objective: The aim of this
study was to test the hypothesis that increasing morbidity would independently predict an increasing risk of 30-day
readmission despite multidisciplinary management of CHF. Methods: We studied patients hospitalized for any
reason with heart failure receiving nurse-led, postdischarge multidisciplinary management. We profiled a matrix of
expected comorbidities involving the most common coexisting conditions associated with CHF and examined the
relationship between multimorbidity and 30-day all-cause readmission. Results: A total of 830 patients (mean age
73 T 13 years and 65% men) were assessed. Multimorbidity was common, with an average of 6.6 T 2.4 comorbid
conditions with sex-based differences in prevalence of 4 of 10 conditions. Within 30 days of initial hospitalization,
216 of 830 (26%) patients were readmitted for any reason. Greater multimorbidity was associated with increasing
readmission (4%Y44% for those with 0Y1 to 8Y9 morbid conditions; adjusted odds ratio, 1.25; 95% confidence
interval, 1.13Y1.38) for each additional condition. Three distinct classes of patient emerged: class 1Vdiabetes,
metabolic, and mood disorders; class 2Vrenal impairment; and class 3Vlow with relatively fewer comorbid
conditions. Classes 1 and 2 had higher 30-day readmission than class 3 did (adjusted P G .01 for both comparisons).
Conclusions: These data affirm that multimorbidity is common in adult CHF inpatients and in potentially distinct
patterns linked to outcome. Overall, greater multimorbidity is associated with a higher risk of 30-day all-cause
readmission despite high-quality multidisciplinary management. More innovative approaches to target-specific
clusters of multimorbidity are required to improve health outcomes in affected individuals.
KEY WORDS: chronic heart failure, disease management, multimorbidity, premature readmission
Joshua F. Wiley, PhD
Postdoctoral Fellow, Mary MacKillop Institute for Health Research,
Australian Catholic University, Melbourne, Australia.
Yih-Kai Chan, PhD
Research Fellow, Mary MacKillop Institute for Health Research,
Australian Catholic University, Melbourne, Australia.
Yasmin Ahamed, PhD
Postdoctoral Fellow, Mary MacKillop Institute for Health Research,
Australian Catholic University, Melbourne, Australia.
Jocasta Ball, PhD
NHMRC/NHFA Early Career Fellow, Mary MacKillop Institute
for Health Research, Australian Catholic University, Melbourne,
Australia.
Melinda J. Carrington, PhD
Associate Professor, Mary MacKillop Institute for Health Research,
Australian Catholic University, Melbourne, Australia.
Barbara Riegel, PhD
Professor, University of Pennsylvania School of Nursing, Philadelphia.
Simon Stewart, PhD
Director, Mary MacKillop Institute for Health Research, Australian
Catholic University, Melbourne, Australia.
TheWHICH? andWHICH? II Trials are supported by theNational Health and
Medical Research Council of Australia project funds (identification 418967
and 1049133). S.S. (APP1041796) and J.B. (APP1112829) are supported by
the National Health and Medical Research Council of Australia. J.B. is also
supported by a Postdoctoral Fellowship (Award Reference 100950) from
the National Heart Foundation of Australia and M.J.C. is supported by a
Future Leader Fellowship (Award Reference 100802) from the National
Heart Foundation of Australia.
The authors have no conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL
citations appear in the printed text and are provided in the HTML and PDF
versions of this article on the journal’s Website (www.jcnjournal.com).
Correspondence
Simon Stewart, PhD, Mary MacKillop Institute for Health Research,
Australian Catholic University, Level 5, 215 Spring St, Melbourne,
Victoria 3000, Australia (simon.stewart@acu.edu.au).
DOI: 10.1097/JCN.0000000000000391
437
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Despite an evolving armory of pharmacologicalagents,1 device-based therapies,2 disease manage-
ment strategies,3 and improved outcomes,4 chronic
heart failure (CHF) continues to be associated with
premature mortality5 and recurrent hospitalization.6
Within the ageing populations of high-income countries,
CHF-related admissions continue to rise overall because
of an increasing pool of at-risk individuals (noting in-
cident admission rates are declining)7 and recurrent and
often unavoidable hospitalization.8 The latter compo-
nent of increasing hospital activity attributable to CHF
is undoubtedly linked to the increasing clinical com-
plexity of prevalent cases as reflected in the presence of
CHF and multimorbidity. In this study, multimorbidity
is defined as the presence of CHF and 2 or more con-
current conditions other than its antecedent hyper-
tension and coronary artery disease.9 Multimorbidity
represents both a challenge and an opportunity for dis-
ease management programs given recent evidence sug-
gesting that, despite their ability to prolong days alive
and out-of-hospital overall, a blanket approach to apply-
ing disease management can potentially provoke poorer
health outcomes (more events) in those with multi-
morbidity.10 US Medicare data show that 81% of total
in-patient hospital days are accumulated by 40% of
individuals with CHF who have 5 or more noncardiac
comorbidities.11 Increasing multimorbidity in CHF has
been linked to increasing risk of 30-day readmission.12
Whether this phenomenon persists in the setting of mul-
tidisciplinary management of CHF recommended by
expert guidelines13,14 remains unclear.
We recently published a framework and multimor-
bidity matrix: Acknowledge, Routinely profile, Identify,
Support, and Evaluate Heart Failure (ARISE-HF) dem-
onstrating the complex pathways between common
multimorbid conditions for systematically screening and
managing this increasingly complex patient population.9
We identified the top 10 cardiac and noncardiac co-
morbid conditions commonly affecting patients with
CHF15 along with recommendations for systematic
screening of hospitalized patients to determine levels
of multimorbidity. Our results also identified that the
efficacy of existing CHF management programs would
likely be eroded as the clinical/pathophysiological
complexity of the patient increases.16,17 On this basis,
there is an urgent need to fully investigate the nature
and impact of multimorbidity in CHF in the setting of
‘‘optimal’’ postdischarge multidisciplinary management.
Study Aims and Hypotheses
We examined the characteristics and potential impact
of multimorbidity on 30-day all-cause readmission in
older patients with CHF exposed to a gold-standard,
postdischarge multidisciplinary management program
specifically designed to reduce recurrent hospitalization
and prolong survival in the longer-term. First, we tested
the hypothesis that increasing morbidity would inde-
pendently predict an increasing risk of 30-day readmis-
sion despite high-quality multidisciplinary management.
Consistent with the ARISE-HF framework,9 we fur-
ther hypothesized that there would be distinct patterns
or clusters of multimorbidity that could inform the
modification/adaptation of existing CHF management
programs to enhance their ability to optimize health out-
comes in this increasingly prevalent patient population.
Methods
Study data were derived from 2 contiguous multicenter
randomized controlled trials with equivalent baseline
profiling of multimorbidity and 30-day readmissions.
The Which Heart Failure Intervention is Most Cost-
effective & Consumer Friendly in Reducing Hospital
Care (WHICH?) Trial16 comprised 280 patients enrolled
in a home versus clinic-based management (WHICH?
TrialYAustralia and New Zealand Clinical Trial Registry
12607000069459). An additional 550 patients came
from an ongoing (30-day data collection completed
February 2016) sequel trial of standard versus intensified
and titrated home and structured telephone follow-up
(WHICH? II TrialYAustralia and New Zealand Clinical
Trial Registry 12613000921785). These 2 closely related
CHF management trials recruited equivalent patient
cohorts from 5 tertiary referral hospitals and managed
within the context of a subsidized Australian healthcare
system. Both studies conform to the principles outlined
in the Declaration of Helsinki with appropriate human
ethic approvals granted by relevant governing committees.
Study Cohort
The same clinical eligibility criteria and standardized
protocols were applied in both trials.18 Hospitalized
individuals with CHF were systematically screened for
eligibility to participate in either of the 2 studies and
were included if they (1) were 18 years or older, (2)
could provide informed consent, (3) were discharged to
home with a cardiologist-confirmed diagnosis of CHF
(based on symptoms and echocardiography), (4) had
persistent moderate to severe functional impairment
(New York Heart Association class IIYIV), and (5) had
a history of 1 or more admission for acute heart failure
in the past 12 months (including the index admission).
Those with a terminal malignancy were excluded. Nine
patients participated in both studies.
Clinical Management
Postdischarge, multidisciplinary management was ex-
plicitly guided by expert guidelines and standardized
across study sites.13,18Y20 Although both study arms in
both trials received multidisciplinary management,
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there were key differences in the intervention arm that
could potentially influence the pattern of recurrent read-
mission in the short-to-longer-term. In the WHICH?
Trial, the same principles and structure of multidis-
ciplinary management were delivered via a specialist
CHF clinic or a home-based intervention. Home-based
intervention was superior to specialist CHF clinic in the
medium to longer-term (with respect to survival and
recurrent hospital stay),16,17 but there was no substan-
tive difference in 30-day readmissions.16 In the WHICH?
II Trial, the same combination of nurse-led, multidis-
ciplinary, home-based intervention with access to a
specialist CHF clinic at the patient’s treating hospital is
applied in both study arms in the short-term. In the
trial intervention arm, this standardized approach is
supplemented by structured telephone support and the
overall intensity of management in the longer-term is
titrated to clinical need. Similar to the WHICH? Trial,
we anticipate no substantive differences in the pattern
of 30-day readmission according to group assignment
in the WHICH? II Trial. Regardless of the manage-
ment approach, following hospital discharge, all study
patients had unrestricted access to specialist outpatient
management, primary care physicians, subsidized phar-
macological treatment and referral to allied healthcare
services when required.
Study Data
Patients were comprehensively profiled at baseline
using a combination of face-to-face interview, systematic
review of medical records, application of validated
assessment tools, and questionnaires to measure and
quantify their psychosocial and clinical profiles. Data
were collected via standardized case report forms ad-
ministered by trained personnel. As described in the
original reports,16,18 a detailed demographic and clini-
cal profile (including precipitating factors, prescribed
pharmacotherapy, all diagnoses, functional status and
echocardiographic parameters) was collected for each
patient. The criteria and recommended methods used
to identify the 10 key comorbid conditions relevant to
the ARISE-HF matrix are summarized in Table 1.9
Electronic health records were used to identify all re-
current hospitalization within 30 days of discharge
from the index admission.
Statistical Analyses
Assuming that 20% to 30% of patients experience
a 30-day readmission, a sample size of more than
800 patients with CHF provides 80% power to detect
a modest but meaningful odds ratio (OR) of 1.6 to 1.7
for morbid conditions with a prevalence of between
25% and 75% and 160 readmissions, supporting a
multivariate logistic regression with up to 16 pre-
dictors, based on recommendations to have 10 events
per predictor.31
Continuous and categorical data are presented as
mean T standard deviation and frequency (with per-
centage), respectively. A backward multiple logistic
regression model (including sex, age, left ventricular
ejection fraction, blood pressure, body mass index,
estimated glomerular filtration rate, New York Heart
Association class and Charlson Comorbidity Score),
with calculation of OR and 95% confidence interval
(CI) was used to identify the significant correlates of
30-day readmission.
To identify patterns of comorbidities, latent class
analyses32 were conducted on the 10 prespecified co-
morbid conditions. Latent class analysis is a statistical
approach that assumes that there are distinct classes of
patients and those within a class are more similar to
each other than those in a different class.32 It is used to
describe heterogeneity in a population by finding clusters
or classes that account for the observed heterogeneity
and has been successfully applied to better understand
other subgroups of patients with conditions such as
hypertension,33 cancer,34 or depression.35 We applied
latent class analysis to search for distinct clusters of
similar patients with CHF.36,37 For example, in 1 class,
patients may have high rates of metabolic disease, sleep
disorders, and depression or anxiety, whereas in another
class, patients may have high rates of renal impairment
and anemia. Details on the latent class analysis are
presented in the Supplementary Materials, available at
http://links.lww.com/JCN/A30. All data analyses were
performed using SPSS (v 22.0) except for the latent class
analysis, which was performed using Mplus (v 7.3).
Significance was accepted at a 2-sided ! of .05.
Results
Most patients were men (65%) and mean age was 73 T
13 years. Women were approximately 5 years older
than men (P G .05), and more than half (53%) were
living alone (compared with 39% of men). One in
4 patients (25%) was from a nonYEnglish-speaking
background and 72% had fewer than 12 years of edu-
cation (Table 2). Compared with men, women had
more preserved cardiac function (left ventricular ejec-
tion fraction, 44% T 14% vs 35% T 13 %), higher
systolic blood pressure (141 T 31 vs 131 T 26 mmHg),
worse renal function (estimated glomerular filtration
rate, 51 T 22 vs 57 T 22 mL/min/1.73 m2), and lower
serum hemoglobin (121 T 16 vs 128 T 21 g/dL) at
baseline (P G .05 for all comparisons).
Multimorbidity and 30-Day Readmission
Overall, 216 of 830 patients (26%; 95% CI, 23%Y29%)
were readmitted for any cause within 30 days with
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similar proportions for men (27%) and women (25%).
In an unadjusted model, the risk of 30-day readmission
steadily increased with greater levels of multimorbidity
(Figure 1a). Among those with 0 to 1, 2 to 3, 4 to 5, 6
to 7, and 8 to 9 comorbid conditions, 30-day readmis-
sion occurred in 1 of 27 (4%), 39 of 211 (19%), 97 of
366 (27%), 66 of 195 (34%), and 13 of 31 (42%) pa-
tients, respectively. Those readmitted within 30 days
(n = 216) had significantly more comorbid conditions
(5.00 T 1.62 vs 4.31 T 1.68; P G .001). In an adjusted
model (independent of all key clinical and demographic
variables including sex and Charlson Comorbidity Score)
greater multimorbidity predicted 30-day readmission
(OR, 1.25 per additional morbid condition; 95% CI,
1.13Y1.38; P G .001).
Pattern of Multimorbidity According
to Sex
As expected, beyond hypertension (77% women vs
68% men; P G .05) and coronary artery disease (66%
men vs 48% women; P G .05), multimorbidity was
common at index presentation and was closely aligned
with the 10 conditions prespecified in the ARISE-HF
matrix (ie, there were no other significant comorbid
conditions identified, Supplementary Appendix I,
http://links.lww.com/JCN/A30). Figure 1b shows the
broad distribution of comorbid conditions according
to sex. These conditions were normally distributed in
both genders (the most common frequencies at Q3 and
e5 comorbid conditions), with similar means seen in
TABLE 1 Definition and Methods Used to Document and Quantify Multimorbidity in Heart Failure
Comorbidity Data Source and Determination Definition/Deficit Threshold
Anemia Full blood examination during hospital admission Serum Hb level G130 g/L (women)/G120 g/L (men)21
Atrial and ventricular
arrhythmias
Review of medical notes plus review of prescribed
pharmacotherapy at discharge. If high clinical
suspicion of undiagnosed arrhythmiaV12-lead
ECG, inpatient telemetry, or extended ECG
Holter monitoring
Confirmation of AF, other atrial arrhythmias,
second or third degree heart block, and VT/VF
with prescription of antiarrhythmic therapy
or pacemaker/defibrillator device22
Cognitive impairment/
dementia
Assessed via MoCA tool before hospital
discharge by trained personnel
Documented diagnosis of dementia or MoCA score
G26 out of a maximal possible score of 3023
Depression and anxiety Assessed via questionnaire24 before hospital
discharge by trained personnel plus
review of medical notes and prescribed
pharmacotherapy at discharge. If positive,
apply more comprehensive tool (eg, HADS)25
Positive response to depressive symptoms
and/or confirmed diagnosis (with active
antidepressive/anxiolytic) of depression or anxiety
Diabetes and metabolic
disorders
Review of medical notes and prescribed
pharmacotherapy at discharge. Calculation
of BMI. If high clinical suspicion of underlying
diabetes HbA1c and/or glucose tolerance tests.
Documented diagnosis of type 2 diabetes or
obesity (BMI 930 kg/m2) plus dyslipidemia
and/or hypertension (metabolic syndrome)
Musculoskeletal disorders Review of medical notes and prescribed
pharmacotherapy at discharge. Frailty test
with hand-grip manometer, gait speed,
6-minute walk test, and Short Physical
Performance Battery, including static balance,
gait speed, and getting in and out of a chair26
Documented diagnosis of arthritis, osteoporosis, gout,
or any other musculoskeletal condition requiring
active therapy (eg, anti-inflammatory or analgesia)
Renal impairment Electrolytes and renal function obtained
during hospital admission
Estimated glomerular filtration rate27
G60 mL/min/1.73 m2
Respiratory disease Review of medical notes and prescribed
pharmacotherapy at discharge. If high
clinical suspicion of underlying respiratory
diseaseVformal lung function tests
Lung function confirmation of chronic airways
limitation, asthma, and/or other chronic
pulmonary condition requiring active treatment28
Thyroid disease Review of medical notes and prescribed
pharmacotherapy at discharge. If high clinical
suspicion of or historical lack of screening, perform
thyroid function tests (including thyroid stimulating
hormone levels) at hospital admission.
Documented hyperthyroidism/hypothyroidism
according to national standards with associated
antithyroid or thyroxine replacement therapy29
Sleep disorders Review of medical notes and prescribed sleep
support device. If high clinical suspicion of sleep
disordered breathing, perform formal sleep studies.
Use of a screening questionnaire in hospital to
identify those with sleep-disordered breathing.30
Documented diagnosis of obstructive or central
sleep disordered breathing.
Abbreviations: AF, atrial fibrillation; BMI, body mass index; HADS, hospital anxiety and depression scale; Hb, hemoglobin; HbA1c, hemoglobin A1c; ECG,
electrocardiogram; MoCA, Montreal Cognitive Assessment; VF, ventricular fibrillation; VT, ventricular tachycardia. From: Stewart S, Riegel B, Boyd C, et al.
Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement. Int J Cardiol.
2016;212:1Y10. http://dx.doi.org/10.1016/j.ijcard.2016.03.001. Under a Creative Commons license (https://creativecommons.org/licenses/by-nc-nd/4.0/).9
440 Journal of Cardiovascular Nursing x September/October 2018
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
women and men overall (4.57 T 1.68 vs 4.45 T 1.70;
P = .323) and among those 65 years or older (4.65 T
1.65 versus 4.71 T 1.66, P = .686). However, there were
key differentials according to sex on an age-adjusted
basis, including more thyroid disease, depression and
anxiety and moderate-to-severe renal dysfunction in
women and more sleep disorders in men (all compari-
sons P G .05). Reflecting the high prevalence of multi-
morbidity, the majority of patients received extensive
concomitant pharmacotherapies (data not shown) most
commonly including angiotensin converting enzyme
inhibitors, beta-blockers and diuretics (all 990% where
indicated and tolerated).
Clusters of Multimorbidity
There were distinct patterns of multimorbidity that
centered on the 4 most common comorbidities of
arrhythmias (predominantly atrial fibrillation), renal
impairment, respiratory disease, and diabetes and meta-
bolic disease, with slightly different patterns seen in
men and women. Results from the latent class analysis
determined that grouping patients into 3 classes pro-
vided the best empirical fit to the data (Supplementary
Appendix II, http://links.lww.com/JCN/A30). The clas-
ses identified were characterized by distinct patterns
of comorbid conditions (Figure 2). Class 1 comprised
148 of 830 (17.8%) patients with a high prevalence of
comorbid diabetes and metabolic disorders (88.7%),
depression and anxiety (83.8%), sleep disorders
(74.9%), and respiratory disease (74.5%). Class 2 com-
prised 362 of 830 (43.7%) patients who had comorbid
renal impairment (100%) and to a lesser extent elevated
musculoskeletal disorders (41.0%) compared with
Class 3 (17.0%). Class 3 comprised 320 of 830 (38.6%)
patients with the lowest rates of comorbid conditions.
In addition to providing an empirically based approach
to grouping similar patients, the latent class analysis
showed a downward gradient in 30-day readmissions,
with 38.6%, 27.2%, and 18.0% readmitted for classes
1, 2, and 3, respectively. Classes 1 and 2 had signi-
ficantly higher readmission rates than class 3 did (P G
.001 andP = .006, respectively). The difference between
class 1 and 3 remained significant (P = .016) adjusting
for sex, age, living alone, education, history of hyperten-
sion and coronary artery disease, Charlson Comorbidity
Score, and all clinical profile factors from Table 2.
Discussion
To the best of our knowledge, this represents the first study
to comprehensively assess the impact of multimorbidity
TABLE 2 Demographic and Clinical Profile
All (n = 830) Men (n = 539) Women (n = 291)
Demographic profile
Mean age at admission, y 73 T 13 71 T 13 76 T 12a
Living alone 364 (44) 210 (39) 154 (53)a
G12 y of education 592 (72) 350 (65) 242 (84)a
English not first language 206 (25) 139 (26) 67 (23)
Clinical profile
Left ventricular ejection fraction, % 38 T 14 35 T 13 44 T 14a
Heart rate, bpm 87 T 24 87 T 24 87 T 24
Systolic blood pressure, mm Hg 135 T 28 131 T 26 141 T 31a
Diastolic blood pressure, mm Hg 77 T 17 77 T 16 77 T 19
Body mass index, kg/m2 29 T 7 29 T 6 29 T 8
Current smoker 259 (43) 199 (49) 60 (30)
eGFR, mL/min/1.73 m2 55 T 23 57 T 23a 51 T 22
Hemoglobin, g/dL 125 T 20 128 T 21a 121 T 16
Comorbid profile
Charlson comorbidity score 6.6 T 2.4 6.5 T 2.6 6.8 T 2.1
History of hypertension 590 (71) 366 (68) 224 (77)a
Coronary artery disease 494 (60) 354 (66)a 140 (48)
Arrhythmias 583 (70) 387 (72) 196 (67)
Renal impairment 517 (62) 321 (60) 196 (67)a
Diabetes and metabolic disorders 510 (61) 334 (62) 176 (61)
Respiratory disease 409 (49) 261 (48) 148 (51)
Anemia 411 (50) 273 (51) 138 (47)
Depression and anxiety 472 (57) 290 (54) 182 (63)a
Mild cognitive impairment 289 (35) 190 (35) 99 (34)
Musculoskeletal disorders 257 (31) 173 (32) 84 (29)
Sleep disorders 178 (21) 129 (24)a 49 (17)
Thyroid disease 103 (12) 41 (8) 62 (21)a
Data are presented as n (%) or mean T SD.
Abbreviation: eGFR, estimated glomerular filtration rate.
aP G .05 men versus women.
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on 30-day all-cause readmission in the context of high
levels of otherwise effective (at least in the longer-term)
postdischarge multidisciplinary management of CHF.
These data demonstrated that even in the setting of a
multidisciplinary management of CHF program, 26%
of patients experienced a recurrent hospital admission
FIGURE 2. Distribution of morbid conditions by latent class with 95% confidence intervals. Prevalence differences of each
morbid condition by class were tested using #2 tests. ***P G .001, yP = .051.
FIGURE 1. Distribution of multimorbidity in addition to chronic heart failure (CHF) according to (a) hospital readmission
within 30 days and (b) sex. Prevalence differences of each morbid condition by sex were tested using # 2 tests. yP = .054.
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within 30 days. Moreover, the risk of 30-day read-
mission progressively increased with greater multi-
morbidity, ranging from 4% in those with a single
condition to 42% in those with 8 to 9 comorbid con-
ditions. There are also potentially important differences
in the pattern of multimorbidity and risk of 30-day all-
cause readmission according to sex, even though the
risk of readmission was similar in an adjusted model.
Importantly, in the current cohort of older individuals
with CHF, beyond the typical antecedents of hyperten-
sion and coronary artery disease, CHF in isolation is
rare, with most patients having 3 or more additional
comorbid conditions, which complicates their clinical
management and increases their risk for poorer health
outcomes.
Our data are consistent with previous reports of
increased hospitalization risk in the setting of CHF and
multimorbidity,11,38 with 30-day readmission more
likely with increasing comorbidity despite being dis-
charged as (presumed) clinically stable and being exposed
to gold standard, postdischarge multidisciplinary man-
agement of CHF. As is reported in the United States,
CHF in isolation is rare and extremely rare among older
patients.39 As such, multimorbidity in CHF represents
a global phenomenon that reflects the population dy-
namic of increased risk and exposure to chronic disease
with increasing survival from previously fatal events and
greater longevity overall.40,41
As predicted, most (97%) patients in our study were
diagnosed with more than 2 chronic conditions and
more than two-thirds (71%) with more than 4 chronic
conditions (predominately noncardiac). Noncardiac
comorbidities in older adults with CHF are highly
prevalent and are strongly associated with adverse clini-
cal outcomes, including premature death.11 It has been
previously reported that patients with a high burden
of multimorbidity and living in low-income areas have
an elevated risk of rehospitalization or death,42 sug-
gesting that illness burden influences the association
between income and health outcomes in these individ-
uals. Critically, we also identified 3 main patterns of
multimorbidity. Two of these clusters (classes 1 and 2)
were at high risk of 30-day readmission. Class 1 was
characterized by high prevalence of diabetes and meta-
bolic disorders, depression and anxiety, sleep disorders,
and respiratory disease, and class 2, by renal impair-
ment. Combined, these 2 high-risk clusters accounted
for just more than 60% of cases. These data both
confirm and extend previous reports that particular
clusters of comorbidity in CHF are associated with
increasing levels of hospital stay, cost, and death.43
Unfortunately, expert guidelines are yet to articulate
strategies that specifically address the issue of CHF
and multimorbidity.44
This study does not provide causal evidence that
increasing multimorbidity is associated with poorer
health outcomes in the longer-term (ie, beyond 30 days).
However, it still strongly indicates the potential to
improve the efficacy of current CHF management
programs in the setting of multimorbidity. In a recent
composite analysis of trials focusing on the overall
benefits of multidisciplinary, home-based intervention
in the setting of CHF,16,17 chronic atrial fibrillation,45
and chronic heart disease overall,46 there was clear
evidence of a differential effect of this intervention on
survival (and perhaps recurrent hospitalization) accord-
ing to multimorbidity. Higher levels of multimorbidity
were associated with worse outcomes.10 In the current
study, it is difficult to determine if we are observing (a)
the early stages of the same phenomenon (ie, a dele-
terious response to proactive home-based, CHF man-
agement), (b) triggering of early readmissions that are
therapeutic (by proactively addressing critical clinical
issues) in the longer-term, or (c) a combination of the
both. Certainly, this is an important area for further
scrutiny and research.
Consistent with the idea of adopting a goal-orientated
approach that identifies multimorbidity as a distinct
clinical entity,47 our mapping of the potentially com-
plex matrix of multimorbidity in CHF reveals multi-
ple intervention points to improve health outcomes.9
Although it is challenging to develop interventions that
optimally adapt to all possible combinations of comor-
bid conditions, the 3 empirical clusters of patients we
identified in this study may be a pragmatic starting
point. Tailoring interventions to a CHF patient-centric
disease profile may well improve outcomes compared
to a ‘‘one size fits all’’ approach. Interventions derived
from disease profiles may be more feasible as they are
strategic management plans based on the most common
patterns of disease rather than trying to respond to
every possible combination of multimorbidity. For the
training heart failure nurses, there are practical impli-
cations for widening curricular to incorporate a wider
spectrum of clinical management skills directed toward
complex patients with CHF and multimorbidity. This is
particularly true when considering that 2 clusters were
associated with worse outcomes. Building upon these
data and with ongoing validation of the ARISE-HF
matrix, our group is currently mapping out the best
way to address multimorbidity in CHF as part of an
attempt to develop and test a cost-effective intervention
for affected individuals.
Limitations
This was a retrospective cohort study from and in-
cluded an ethnically diverse cohort (many with English
as a second language) reflecting the multicultural diver-
sity of Australia. We have combined outcome data from
contiguous trials with equivalent baseline profiling of
multimorbidity but some differences between the
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adjudication of multimorbidity may have occurred.
Moreover, at this time, we are unable to consider the
role of treatment adherence and self-care behaviors in
determining the risk of 30-day readmission. We also
did not specifically account for visual and hearing
deficits and health literacy issues (these are routinely
assessed but not formally documented at baseline) that
should be factored into future analyses of this kind.
Pending formal assessment of all trial events, we have
only examined 30-day readmissions on an ‘‘all-cause’’
basis. Lastly, we have yet to examine the impact of
multimorbidity on long-term outcomes.
Conclusion
Our findings confirm that multimorbidity is common
among hospitalized patients with CHF. Moreover, we
found that even in those exposed to multidisciplinary
CHF management (with minimum standards of care
applied), increasing multimorbidity per se was associated
with a parallel increase in all-cause 30-day readmissions.
This is a major issue for individuals and the healthcare
system as a whole. In light of our evidence of common
clusters of comorbid conditions in CHF, developing
and testing novel interventions tailored to patients in
each of these clusters may be a key direction for future
clinical research and trials.
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